| 1. |
Recommendations for inhaled antibacterials in cystic fibrosis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 2-2
&NA;,
Preview
|
PDF (905KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 2. |
… and AHA statement on recurrent ischaemic stroke prevention |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 3-3
&NA;,
Preview
|
PDF (790KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 3. |
Acid-related effects of alendronic acid costly |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 4-4
&NA;,
Preview
|
PDF (763KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 4. |
Omeprazole good value for money in acid-related dyspepsia |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 5-5
&NA;,
Preview
|
PDF (818KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 5. |
Anti-idiotype CEA antibody vaccine breaks immune tolerance |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 6-6
&NA;,
Preview
|
PDF (819KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 6. |
Methylprednisolone injection proximal to carpal tunnel beneficial |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 7-7
&NA;,
Preview
|
PDF (718KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 7. |
News from the 21st Congress of the European Society of CardiologyBarcelona, Spain August-September 1999 |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 8-9
&NA;,
Preview
|
PDF (1571KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 8. |
Panic disorder news … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 9-9
&NA;,
Preview
|
PDF (767KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 9. |
News in brief … |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 10-10
&NA;,
Preview
|
PDF (816KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
| 10. |
Paclitaxel plus doxorubicin as first-line treatment for breast cancer? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1208,
1999,
Page 11-12
Carmen Innes,
Preview
|
PDF (1680KB)
|
|
摘要:
Paclitaxel in combination with doxorubicin significantly prolongs median time to disease progression in patients with metastatic breast cancer, according to the results of a multinational phase III study.1The combination also improves overall survival. The study, which was presented at the 10th European Conference on Clinical Oncology [Vienna, Austria; September 1999] compared the paclitaxel and doxorubicin combination with fluorouracil plus doxorubicin and cyclophosphamide (FAC), which is considered to be standard first-line therapy for women with metastatic disease. Patients who received paclitaxel plus doxorubicin had a significantly longer time to disease progression, greater response to treatment and improved overall survival duration, compared with patients who received FAC. Leading investigators from the trial say that the paclitaxel regimen is superior to the FAC regimen, and warrants immediate further development.
ISSN:1173-8324
出版商:ADIS
年代:1999
数据来源: ADIS
|
首页
